Clinical aspects and therapy of hemophagocytic lymphohistiocytosis

Histiocytic Disorders of Children and Adults

Volumn , Issue , 2005, Pages 353-379

  Janka, Gritta ^a   Jan Inge, Henter ^b   Imashuku, Shinsaku ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Kyoto City Institute of Healt   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29244444642     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545252.019     Document Type: Chapter

References (113)

1. Allen, M., De Fusco, C., Legrand, F., et al. (2001). Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica,86,499-503.
2. Allory, Y., Challine, D., Haioun, C., et al. (2001). Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am J Surg Path,25, 865-874.
3. Ambruso, D.R., Hays, T., Zwartjes, W.J., et al. (1980). Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer,45,2516-2520.
4. Arico, M., Janka, G., Fischer, A., et al. (1996). Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia, 10, 197-203.
5. Arico, M., Allen, M., Brusa, S., et al. (2002). Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression. Br J Haematol,119, 180-188.
6. Baker, K.S., DeLaat, C.A., Steinbuch, M., et al. (1997). Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood,89, 3857-3863.
7. Blanche, S., Caniglia, M., Girault, D., et al. (1991). Treatment of hemophagocytic lymphohistio- cytosis with chemotherapy and bone marrow transplantation: a single-center study of 22 cases. Blood,78, 51-54.
8. Chan, J.K. and Ng, C.S. (1989b). Malignant lymphoma, natural killer cells and hemophagocytic syndrome. Pathology,21, 154-155.
9. Chan, E.Y., Pi, D., Chan, G.T., et al. (1989a). Peripheral T-cell lymphoma presenting as hemo- phagocytic syndrome. Hematol Oncol, 7, 275-285.
10. Chen, R.L., Lin, K.H., Lin, D.T., et al. (1995). Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol, 89, 282-290.
11. Chen, J.S., Lin, K.H., Lin, D.T., et al. (1998). Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens. Br J Haematol, 103, 756-762.
12. Dolezal, M.V., Kamel, O.W., van de Rijn, M., et al. (1995). Virus-associated hemophagocytic syndrome characterized by clonal Epstein-Barr virus genome. Am J Clin Pathol,103, 189-194.
13. Dufourcq-Lagelouse, R., Pastural, E., Barrat, F.J., et al. (1999). Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review). Int JMolecMed,4, 127-133.
14. Duerken, M., Horstmann, M., Bieling, P., et al. (1999). Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br J Haematol,106, 1052-1058.
15. Duval, M., Fenneteau, O., Doireau, V., et al. (1999). Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. JPediatr,134, 236-239.
16. Eife, R., Janka, G.E., Belohradsky, B.H. et al. (1989). Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol,6, 265-272.
17. Falini, B., Pileri, S., De Solas, I., et al. (1990). Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood,75,434-444.
18. Farquhar, J.W. and Claireaux, A.E. (1952). Familial haemophagocytic reticulosis. Arch Dis Child,27,519-525.
19. Fischer, A., Virelizier, J.L., Arenzana-Seisdedos, F., et al. (1985). Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation. Pediatrics, 76, 263-268.
20. Fischer, A., Cerf-Bensussan, N., Blanche, S., et al. (1986). Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr,108,267-270.
21. Fisman, D.N. (2000). Hemophagocytic syndromes and infection. Emerg Infect Dis,6, 601-608.
22. Freeman, B., Rathore, M.H., Salman, E., et al. (1993). Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome. J Pediatr, 123, 479-481.
23. Fujii, N., Takenaka, K., Hiraki, A., et al. (2000). Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant, 26, 805-808.
24. Garbagnati, E. (1993). Changes in lipid profile observed in children over the course of infectious disease. Acta Paediatr,82, 948-952.
25. Grom, A.A., Villanueva, J., Lee, S., et al. (2003). Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr, 142,292-296.
26. Hadchouel, M., Prieur, A.M. and Griscelli, C. (1985). Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr,106, 561-566.
27. Haddad, E., Sulis, M.L., Jabado, N., et al. (1997). Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood,89, 794-800.
28. Henter, J.-I. and Elinder, G. (1991). Familial hemophagocytic lymphohistiocytosis. Clinical review based on the findings in seven children. Acta Paediatr Scand,80, 269-277.
29. Henter, J.-I. and Elinder, G. (1992). Cerebromeningeal haemophagocytic lymphohistiocytosis. Lancet,339, 104-107.
30. Henter, J.-I. and Nennesmo, I. (1997). Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J Pediatr,130, 358-365.
31. Henter, J.-I., Elinder, G., Soder, O. et al. (1991a). Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand,80, 428-435.
32. Henter, J.-I., Carlson, L.A., Soeder, O., et al. (1991b). Lipoprotein alterations and plasma lipoprotein lipase reduction in familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand, 80, 675-681.
33. Henter, J.-I., Elinder, G. and Ost, A. (1991c). Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol,18,29-33.
34. Henter, J.-I., Ehrnst, A., Andersson, J., et al. (1993). Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr,82, 369-372.
35. Henter, J.-I., Arico, M., Egeler, R.M., et al. (1997). HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol, 28, 342-347.
36. Henter, J.-I., Samuelsson-Horne, A., Arico, M., et al. (2002). Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood,100, 2367-2373.
37. Hirai, H., Shimazaki, C., Hatsuse, M., et al. (2001). Autologous peripheral blood stem cell transplantation for adult patients with B-cell lymphoma-associated hemophagocytic syndrome. Leukemia,15, 311-312.
38. Ikeda, H., Kato, M., Matsunaga, A., et al. (1998). Multiple sulphatase deficiency and haemophago- cytic syndrome. Eur J Pediatr,157, 553-554.
39. Imashuku, S. (2002). Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Reviews Hematol/Oncol,44, 259-272.
40. Imashuku, S., Hibi, S., Tabata, Y., et al. (1998). Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol,31, 131-137.
41. Imashuku, S., Hibi, S., Ohara, T., et al. (1999a). Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood,93, 1869-1874.
42. Imashuku, S., Hibi, S., Todo, S., et al. (1999b). Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Bone Marrow Transplant,23,569-572.
43. Imashuku, S., Hibi, S., Kuriyama, K., et al.(2000a). Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lympho- histiocytosis. Leuk Lymphoma,36, 339-346.
44. Imashuku, S., Hibi, S., Tabata, Y., et al. (2000b). Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma,37, 577-584.
45. Imashuku, S., Kuriyama, K., Teramura, T., et al. (2001). Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol,19, 2665-2673.
46. Imashuku, S., Teramura, T., Kuriyama, K., et al. (2002). Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol,75, 174-177.
47. Imashuku, S., Kuriyama, K., Sakai, R., et al. (2003). Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol,41, 103-109.
48. Imashuku, S., Teramura, T., Tauchi, H., et al. (2004). Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica,89, 183-188.
49. Ishihara, S., Okada, S., Wakiguchi, H., et al. (1995). Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr,84, 1271-1275.
50. Jabado, N., de Graeff-Meeder, E.R., Cavazzana-Calvo, M., et al. (1997). Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood,90, 4743-4748.
51. Jaffe, E.S., Costa, J., Fauci, A.S., et al. (1983). Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med,75, 741-749.
52. Janka, G.E. (1983). Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr,140, 221-230.
53. Janka, G.E. (1989). Familial hemophagocytic lymphohistiocytosis: therapy in the German experience. Pediatr Hematol Oncol,6,227-231.
54. Janka, G.E. and Schneider, E.M. (2004). Modern management of children with haemophago- cytic lymphohistiocytosis. Br J Haematol,124,4-14.
55. Janka, G., Imashuku, S., Elinder, G., et al. (1998). Infection- and malignancy-associated hemo- phagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am,12, 435-444.
56. Janka-Schaub, G.E., Rosenberger, M., Lorenz, I., et al. (1999). Hemophagocytic lymphohistiocytosis: clinical variability and usefulness of diagnostic parameters. Med Pediatr Oncol, 33,517.
57. Janka, G.E., Muller-Rosenberger, M. and Schneider, E.M. (2000). Persistent defect of cellular cytotoxicity after Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (HLH). Blood,96, 36b.
58. Kadin, M.E., Kamoun, M. and Lamberg, J. (1981). Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. New Engl J Med, 304, 648-653.
59. Kanegane, H., Nomura, K., Miyawaki, T., et al. (2002). Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit Reviews Hematol Oncol, 44, 239-249.
60. Katano, H., Ali, M.A., Patera, A.C., et al. (2004). Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood,103, 1244-1252.
61. Kawa, K. (2003). Diagnosis and treatment of Epstein-Barr virus-associated natural killer lym- phoproliferative disease. Int J Hematol,78,24-31.
62. Kawaguchi, H., Miyashita, T., Herbst, H., et al. (1993). Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest,92, 1444-1450.
63. Kieslich, M., Vecchi, M., Driever, P.H., et al. (2001). Acute encephalopathy as a primary manifestation of haemophagocytic lymphohistiocytosis. Develop Med Child Neurol,43, 555-558.
64. Kikuta, H. and Sakiyama, Y. (1995). Etoposide (VP-16) inhibits Epstein-Barr virus determined nuclear antigen (EBNA) synthesis. Br J Haematol,90, 971-973.
65. Kikuta, H., Sakiyama, Y., Matsumoto, S., et al. (1993). Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood,82, 3259-3264.
66. Kimura, H., Morita, M., Yabuta, Y., et al. (1999). Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol,37, 132-136.
67. Kitazawa, J., Ito, E., Arai, K., et al. (2001). Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohis- tiocytosis. Med Pediatr Oncol,37, 153-154.
68. Kogawa, K., Lee, S.M., Villanueva, J., et al. (2002). Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood,99, 61-66.
69. Komp, D.M., McNamara, J. and Buckley, P. (1989). Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood,73, 2128-2132.
70. Loechelt, B.J., Egeler, M., Filipovich, A.H., et al. (1994). Immunosuppression: preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistiocytosis (FHL). Med Pediatr Oncol,22, 325-328.
71. Mandel, H., Gozal, D., Aizin, A., et al. (1990). Haemophagocytosis in hereditary fructose intolerance: a diagnostic dilemma. J Inherited Metabol Dis,13,267-269.
72. Matsumoto, Y., Naniwa, D., Banno, S., et al. (1998). The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Therapeutic Apheresis, 2, 300-304.
73. Mitarnun, W., Suwiwat, S., Pradutkanchana, J., et al. (2002). Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis. Am J Hematol,70, 31-38.
74. Molleran Lee, S., Villanueva, J., Sumegi, J., et al. (2004). Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet,41, 137-144.
75. Mouy, R., Stephan, J.L., Pillet, P., et al. (1996). Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr,129, 750-754.
76. Mroczek, E.C., Weisenburger, D.D., Grierson, H.L., et al. (1987). Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med,111, 530-535.
77. Mueller-Rosenberger, M. (2004). Histiozytare Hamophagozytosesyndrome bei Kindern; Klinik, Verlaufund funktionelle immunologische Diagnostik, Thesis University Hamburg, Hamburg.
78. Murase, T. and Nakamura, S. (1999). An Asian variant of intravascular lymphomatosis: an updated review of malignant histiocytosis-like B-cell lymphoma. Leuk Lymphoma,33,459-473.
79. Nomura, S., Koshikawa, K., Hamamoto, K., et al. (1992). Steroid and gamma globulin therapy against virus-associated hemophagocytic syndrome. Rinsho Ketsueki,33, 1242-1247.
80. Ohno, T., Miyake, N., Hada, S., et al. (1998). Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma. Cancer,82, 1963-1972.
81. Ohno, T., Ueda, Y., Nagai, K., et al. (2003). The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas. Int J Hematol,77, 286-294.
82. Okamura, T., Hatsukawa, Y., Arai, H., et al. (2000). Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet,356,223-224.
83. Okamura, T., Kishimoto, T., Inoue, M., et al. (2003). Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant, 31, 105-111.
84. Oyama, Y., Amano, T., Hirakawa, S., et al. (1989). Haemophagocytic syndrome treated with cyclosporin A: a T cell disorder? Br JHaematol,73, 276-278.
85. Parizhskaya, M., Reyes, J. and Jaffe, R. (1999). Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis. Pediatr Develop Pathol,2, 360-366.
86. Perel, Y., Alos, N., Ansoborlo, S., et al. (1997). Dramatic efficacy of antithymocyte globulins in childhood EBV-associated haemophagocytic syndrome. Acta Paediatr,86, 911.
87. Pracher, E., Grumayer-Panzer, E.R., Zoubek, A., et al. (1993). Bone marrow transplantation during fulminant EBV-infection in Duncan’s syndrome. Lancet,342, 1362.
88. Quintanilla-Martinez, L., Kumar, S., Fend, F., et al. (2000). Fulminant EBV(+) T-cell lympho- proliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood,96,443-451.
89. Ramanan, A.V. and Baildam, E.M. (2002). Macrophage activation syndrome is hemophagocytic lymphohistiocytosis - need for the right terminology. J Rheumatol,29, 1105 (author reply).
90. Reiner, A.P. and Spivak, J.L. (1988). Hematophagic histiocytosis: a report of 23 new patients and a review of the literature. Medicine (Balt),67, 369-388.
91. Risdall, R.J., McKenna, R.W., Nesbit, M.E., et al. (1979). Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer, 44, 993-1002.
92. Rostasy, K., Kolb, R., Pohl, D., et al. (2004). CNS disease as the main manifestation of hemophagocytic lymphohistiocytosis in two children. Neuropediatrics,35, 45-49.
93. Sandlund, J.T., Roberts, W.M., Pui, C.H., et al. (1997). Systemic hemophagocytosis masking the diagnosis of large cell non-Hodgkin lymphoma. Med Pediatr Oncol,29, 167-169.
94. Schneider, E.M., Lorenz, I., Muller-Rosenberger, M., et al. (2002). Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood,100,2891-2898.
95. Shimazaki, C., Inaba, T. and Nakagawa, M. (2000). B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma,38, 121-130.
96. Spieker, T., Kurth, J., Kuppers, R., et al. (2000). Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease. Blood,96, 3133-3138.
97. Stephan, J.L., Donadieu, J., Ledeist, F., et al. (1993). Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood,82,2319-2323.
98. Stephan, J.L., Kone-Paut, I., Galambrun, C., et al. (2001). Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxf),40, 1285-1292.
99. Stine, K.C., Saylors, R.L., Sawyer, J.R. et al. (1997). Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol,15, 1583-1586.
100. Su, I.J., Chen, R.L., Lin, D.T., et al. (1994). Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in Taiwan. Am J Pathol,144,1219-1225.
101. Su, I.J., Wang, C.H., Cheng, A.L., et al. (1995). Hemophagocytic syndrome in Epstein-Barr virus- associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma,19, 401-406.
102. Sullivan, K.E., Delaat, C.A., Douglas, S.D., et al. (1998). Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res, 44, 465-468.
103. Sumazaki, R., Kanegane, H., Osaki, M., et al. (2001). SH2D1A mutations in Japanese males with severe Epstein-Barr virus - associated illnesses. Blood,98, 1268-1270.
104. Sumegi, J., Huang, D., Lanyi, A., et al. (2000). Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoprolif- erative disease. Blood,96, 3118-3125.
105. Takahashi, T., Yagasaki, F., Endo, K., et al. (1998). Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome. Int J Hematol,68, 333-336.
106. Takahashi, N., Chubachi, A., Miura, I., et al. (1999). Lymphoma-associated hemophagocytic syndrome in Japan. Rinsho Ketsueki,40, 542-549.
107. Takami, A., Nakao, S., Ueda, M., et al. (2000). Successful treatment of B-cell lymphoma associated with hemophagocytic syndrome using autologous peripheral blood CD34 positive cell transplantation followed by induction of autologous graft-versus-host disease. Ann Hematol, 79,389-391.
108. Teramura, T., Tabata, Y., Yagi, T., et al. (2002). Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma,43, 173-179.
109. Tsuji, Y., Ayaki, H., Whitman, S.P., et al. (2000). Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol,20, 5818-5827.
110. Ueda, I., Morimoto, A., Inaba, T., et al. (2003). Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br J Haematol,121, 503-510.
111. Wulffraat, N.M., Rijkers, G.T., Elst, E., et al. (2003). Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxf),42, 375-379.
112. Yagita, M., Iwakura, H., Kishimoto, T., et al. (2001). Successful allogeneic stem cell transplantation from an unrelated donor for aggressive Epstein-Barr virus-associated clonal T-cell proliferation with hemophagocytosis. Int J Hematol,74,451-454.
113. Zheng, C., Schneider, E.M., Samuelsson-Horne, A.C., et al. (2004). Natural killer cell activity subtypes provide therapeutic guidance in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 43, 200.